PubMed=23230188; DOI=10.1158/2159-8290.CD-12-0197; PMCID=PMC3531869
Braas D., Ahler E., Tam B.M., Nathanson D., Riedinger M., Benz M.R., Smith K.B., Eilber F.C., Witte O.N., Tap W.D., Wu H., Christofk H.R.
Metabolomics strategy reveals subpopulation of liposarcomas sensitive to gemcitabine treatment.
Cancer Discov. 2:1109-1117(2012)

PubMed=23416162; DOI=10.1016/j.ajpath.2013.01.002; PMCID=PMC3620414
Smith K.B., Tran L.M., Tam B.M., Shurell E.M., Li Y.-F., Braas D., Tap W.D., Christofk H.R., Dry S.M., Eilber F.C., Wu H.
Novel dedifferentiated liposarcoma xenograft models reveal PTEN down-regulation as a malignant signature and response to PI3K pathway inhibition.
Am. J. Pathol. 182:1400-1411(2013)

PubMed=26643872; DOI=10.18632/oncotarget.6464; PMCID=PMC4767443
Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K., Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U., Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Myklebost O., Yang H.H., Dugas M., Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S., Koeffler H.P.
Genomic landscape of liposarcoma.
Oncotarget 6:42429-42444(2015)